louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05419869: Pilot Decentralized Trial
Official title: An Open-Label Study of ALTO-100 in Adults With Major Depressive Disorder (MDD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Major Depressive Disorder
Lead sponsor: Alto Neuroscience
Sponsor class: INDUSTRY
First posted: 2022-06-15
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-100.


Eligibility criteria: Inclusion Criteria:

* Have a diagnosis of moderate to severe major depressive disorder
* Either currently taking a SSRI, SNRI, mirtazapine, or bupropion for at least 6 weeks with no dose modifications in the past 2 weeks, or are not taking an antidepressant medication
* Willing to comply with all study assessments and procedures
* Must not be pregnant or breastfeeding at time of enrollment or throughout study
* Must have access with privacy to a computer with a keyboard and internet

Exclusion Criteria:

* Evidence of acute or unstable cardiovascular, respiratory, hepatic, or other major disease
* Active suicidal ideation
* Severe impediment to vision, hearing, and/or hand movement
* Diagnosed bipolar disorder or psychotic disorder
* Has a history of hypersensitivity or allergic reaction to ALTO-100 or any of its components/excipients
* Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device

Primary outcomes:
measure: To understand the relationship between baseline biology and score change in the Montgomery-Asberg Depression Rating Scale (MADRS) with ALTO-100 from start of dosing to end of treatment
timeFrame: Measured at Day 1, Day 14, Day 28, Day 42, Day 56
measure: To understand the relationship between baseline biology and score change in the Clinical Global Impression scale - Severity (CGI-S) with ALTO-100 from Screening to end of treatment
timeFrame: Measured at Screening, Day 1, Day 14, Day 28, Day 42, Day 56
measure: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability of ALTO-100
timeFrame: From the signing of the ICF until the follow-up visit (up to 13 weeks)
measure: Number of Participants With Clinically Significant Laboratory Abnormalities as a Measure of Safety and Tolerability of ALTO-100
timeFrame: From the signing of the ICF until the end-of-treatment visit (up to 13 weeks)
Secondary outcomes:
Other outcomes:
Locations:
city: Coral Gables
country: United States
facility: Site 160
state: Florida
city: Jackson
country: United States
facility: Site 156
state: Mississippi
Study officials:
References:
Clinical trial NCT00569569: Retaane® in Age-Related Macular Degeneration
Official title: Retaane® in Age-Related Macular Degeneration
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Age Related Macular Degeneration
Lead sponsor: Rudolf Foundation Clinic
Sponsor class: OTHER
First posted: 2007-12-07
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration currently presents a great challenge. With visual loss threatening, there are only very few therapeutic options.

While these patients are neither suitable for laser therapy nor for photodynamic therapy with Verteporfin, antiangiogenic drugs applied intravitreally are now available.

Some patients however reject this therapeutic option because of potential complications such as endophthalmitis and the frequency of necessary injections. 20 patients who rejected intravitreal therapy were treated with Anecortave acetate (Retaane®) which was applied as a juxtascleral depot injection.


Eligibility criteria: Inclusion Criteria:

* rejection of intravitreal injections
* presence of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration

Exclusion Criteria:

* conditions precluding judgement of the fundus

Primary outcomes:
measure: Increase in VA
timeFrame: 6 months
Secondary outcomes:
measure: Decrease in Macula Edema
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
affiliation: no affiliation
name: Susanne Binder, M.D.
role: STUDY_CHAIR
References:
Clinical trial NCT06363669: Effects of Caffeine-based Supplement on Physical Performance
Official title: Acute Effects of Multi-ingredient Pre-workout Dietary Supplement on Physical Performance in Untrained Men
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Muscle Power
Keywords: exercise
caffeine
muscle power
Lead sponsor: University School of Physical Education, Krakow, Poland
Sponsor class: OTHER
First posted: 2024-04-12
Enrollment: 12
Sex: MALE
Minimum age (years): 19
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: The aim of the study was to determine the acute effects of multi-ingredient pre-workout supple-ment (MIPS) containing: beta-alanine, taurine, caffeine, L-tyrosine, and cayenne pepper (capsaicin) on physical performance in untrained men

Detailed description: The aim of our study was to determine the acute effects of commercially available multi-ingredient pre-workout supple-ment (MIPS) containing: beta-alanine, taurine, caffeine, L-tyrosine, and cayenne pepper (capsai-cin) on physical performance in untrained men. The aerobic and anaerobic capacity was determined after ingestion of MIPS. A randomized, crossover, single-blind design was used to evaluate the effects of the dietary supplement on physical performance. The participants performed the exercise test twice, in random order: as a control test and after supplement administration (MIPS). The measurements took place over two consecutive days. Somatic measurements were taken on the same day that the first all-out test was performed. Twelve young healthy men, without medical contraindications to supramaximal and maximal intensity exercise, participated in the study. The exercise tests took place under medical supervision.

Eligibility criteria: Inclusion Criteria:

lack of neuromuscular and musculoskeletal disorders; no medication nor dietary supplements used within the previous month which could potentially affect the study outcomes and self-described good health status. An additional inclusion criterion was the small amount of caffeine consumed per day, i.e. only one caffeinated coffee drink per day or less.

Exclusion Criteria:

consumption of energy drinks

Primary outcomes:
measure: anaerobic power
timeFrame: one day every 30 minutes
measure: aerobic power
timeFrame: one day every 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Krakow
country: Poland
facility: University School of Physical Education in Cracow
Study officials:
affiliation: University of Physical Education, Kraków, Poland
name: Marcin Maciejczyk, prof.dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00409669: Intraocular Pressure Accuracy and Variability of the Barraquer Tonometer
Official title: Study to Compare the Accuracy and Variability of the Barraquer Tonometer With Other Methods of Tonometry
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Elevated Intraocular Pressure
Keywords: Barraquer tonometer
Intraocular pressure
Tonometry
Lead sponsor: Barnes Retina Institute
Sponsor class: OTHER
First posted: 2006-12-11
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: To determine if the Barraquer tonometer provides an accurate and reliable measurement of intraocular pressure. The Barraquer tonometer is a device used to safely and painlessly measure intraocular pressure.

Detailed description: Intraocular pressure will be checked using four different methods of tonometry. These four methods will include Tonopen, Goldmann applanation tonometry, Schiotz tonometry, and Barraquer tonometer. The data will then be compared to determine the reliability and accuracy of the Barraquer tonometer.

Eligibility criteria: Inclusion Criteria:

1. All patients of Barnes Retina Institute who are scheduled to undergo vitreoretinal surgery.
2. All patients scheduled for routine eye examination at the Washington University Eye Clinic or Barnes Jewish Eye Clinic.
3. All ages (patients seen at these locations are adult patients \>18 years of age).

Exclusion Criteria:

1. Any patient who is seen in the outpatient clinics for an urgent or emergency ophthalmological issue.
2. Any patient who has a contraindication to routine, noninvasive methods of tonometry and/or pachymetry (ie corneal ulcer).

Primary outcomes:
measure: Central corneal thickness as measured by pachymetry
timeFrame: at time of measurement
measure: Intraocular pressure as measured by Schiotz tonometer
timeFrame: at time of measurement
measure: Tonopen
timeFrame: at time of measurement
measure: Barraquer tonometer
timeFrame: at time of measurement
measure: and Perkins tonometer
timeFrame: at time of measurement
Secondary outcomes:
Other outcomes:
Locations:
city: St. Louis
country: United States
facility: Washington University School of Medicine and Barnes Jewish Hospital
state: Missouri
Study officials:
affiliation: Washington University School of Medicine and Barnes Retina Institute
name: Gilbert Grand, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02275468: Fu-zheng-qu-zhuo Oral Liquid Improves Renal Function in Patients of CKD Stage 3 and 4
Official title: Fu-zheng-qu-zhuo Oral Liquid Combined With Integrated Therapy Improves Renal Function in Patients of Chronic Kidney Disease Stage 3 and 4，a Randomized Placebo-Control Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Stage 3 Chronic Kidney Disease
Stage 4 Chronic Kidney Disease
Keywords: Chronic Kidney Disease
eGFR slope
Herbal medicine Fu-zheng-qu-zhuo Oral liquid
Lead sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Sponsor class: OTHER
Collaborators: name: Fangshan Hospital of Traditional Chinese Medicine,
name: Peking University First Hospital
First posted: 2014-10-27
Enrollment: 124
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: a prospective, multicenter (outpatient clinics of the three participating hospitals in Beijing), double blinded and randomized placebo-controlled study.

The study consisted of a 2-week run-in period and a 12-month treatment period.


Eligibility criteria: Inclusion Criteria:

(1) Signed informed consent and aged from 18 to 75 years old. (2) Chronic renal diseases with Glomerular Filtration Rate (GFR) estimated using the CKD Epidemiology Collaboration (CKD-EPI) equation between 15 and 59 ml/min per 1.73 m2 on at least 2 dates separated by at least 90 days but no more than 6 month (the CKD defining window period). (3)Not received other TCM treatment for at least 2 weeks.

Exclusion Criteria:

(1) 50% increase in serum creatinine occurring within 2 month before screening. (2) Immediate need for dialysis. (3) Myocardial infarction or cerebrovascular accident in the 6 month preceding the trial. (4) Connective-tissue disease, obstructive uropathy and renal transplantation. (5) Patients with severe disease in other organs or cancer, psychotic diseases, and active tuberculosis. (6) Treatment with corticosteroid and immunosuppressive agents in recent 3 month. Hemoglobin (Hb) less than 80 g/L. (7) Diabetes Mellitus with uncontrolled Blood Sugar ( glycated hemoglobin （HbA1c） \>8.0%). (8) Enrolled in other trials. (9) Women in pregnancy or lactation.

Primary outcomes:
measure: composite end point
timeFrame: 12 month after the treatmnet and 3 years of the follow up time
Secondary outcomes:
measure: the slope of the eGFR versus observation time
timeFrame: 12 month after the treatment
Other outcomes:
Locations:
city: Beijing
country: China
facility: Guang anmen Hospital, China Academy of Chinese Medical Sciences
state: Beijing
city: Beijing
country: China
facility: Fangshan Hospital of Traditional Chinese Medicine
state: Beijing
city: Beijing
country: China
facility: Guang'an Men Hospital South
Study officials:
affiliation: Guang anmen Hospital, China Academy of Chinese Medical Sciences
name: Jie Wang
role: STUDY_CHAIR
References:
Clinical trial NCT04746768: Frailty Syndrome of Post-cancer Treatment Eldery Patients
Official title: Impact of Exercise and Nutritional Support on the Frailty Syndrome of Eldery Patients in Phase of Post-cancer Treatment
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Frailty Syndrome
Exercise
Nutritional Support
Cancer
Lead sponsor: University Hospital, Grenoble
Sponsor class: OTHER
First posted: 2021-02-10
Enrollment: 100
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Decrease the prevalence of frailty syndrome in individuals with complete response of cancer.


Eligibility criteria: Inclusion Criteria:

* in complete remission from cancer (all type of cancer)
* have a frailty syndrome (positive GFST score)
* ability to provide signed informed consent
* be affiliated with social security or beneficiary of such a scheme

Exclusion Criteria:

* patient with active cancer or any other pathology affecting the prognosis at 5 years
* currently participating or having participated in the month preceding inclusion in another interventional clinical research that may impact the study. This impact is left to the investigator discretion
* subjects referred to articles L1121-5 to L1121-8 of CSP (corresponds to all protected persons: person deprived of liberty by judicial or administrative decision, person subject to legal protection measure)

Primary outcomes:
measure: Change of the prevalence of frailty syndrome in individuals with complete response of cancer
timeFrame: 0, 6 and 12 months
Secondary outcomes:
measure: evaluation of predicitive variables of frailty syndrome reversion
timeFrame: Month 0, 6 and 12
measure: Correlations between physical performance and frailty syndrome and their evolutions
timeFrame: Month 0, 6 and 12
measure: Change from baseline nutritional status during nutritionist support (month 3 and 6) and at the end of empowerment (month 12)
timeFrame: Month 0, 3, 6 and 12
measure: Measure adherence to APA interventions and exercise practices
timeFrame: between month 1 to 6 and between month 6 to 12
measure: Estimation of adherence to nutritional interventions
timeFrame: Month 6 and 12
measure: Measure the durability of long-term activities
timeFrame: Month 6 and 12
measure: Measure health related quality of life on mobility, personal autonomy, current activities, pain/discomfort and anxiety/depression
timeFrame: Month 0, 6 and 12
measure: Sociological study on motivation: evaluation of the perception and experience of treating patients
timeFrame: Month 6 and 12
Other outcomes:
Locations:
city: Grenoble
country: France
facility: CHU de Grenoble
Study officials:
affiliation: University Hospital, Grenoble
name: Gaëtan Gavazzi, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04493268: HYPONATREMIA IN COVID-19 PATIENTS
Official title: HYPONATREMIA AND INFLAMMATION AND CLINICAL OUTCOMES IN HOSPITALIZED COVID-19 PATIENTS
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hyponatremia
Covid19
Corona Virus Infection
Keywords: INFLAMMATION
COVID
CORONA
Lead sponsor: Hospital Nacional Profesor Alejandro Posadas
Sponsor class: OTHER
First posted: 2020-07-30
Enrollment: 250
Sex: ALL
Minimum age (years): 1
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: GENERAL POPULATION

Brief summary: SYSTEMIC INFLAMMATION HAS BEEN ASSOCIATED WITH SEVERE COVID-19. HYPONATREMIA CAN RESULT FROM INFLAMMATION DUE TO NON-OSMOTIC STIMULI FOR VASOPRESSIN PRODUCTION. IN THIS PROSPECTIVE COHORT STUDY WE ANALIZED DATA FROM PATIENTS WITH COVID-19 AND THE ASOCIATION WITH HYPONATREMIA AND CLINICAL OUTCOMES.


Eligibility criteria: Inclusion Criteria:

* PATIENTS WITH SARS-CoV-2 INFECTION CONFIRMED BY PCR OF NASOPHARYNGEAL SWABS.

Exclusion Criteria:

-

Primary outcomes:
measure: MORTALITY
timeFrame: 30 DAYS
Secondary outcomes:
measure: ICU HOSPITALIZATION
timeFrame: 30 DAYS
Other outcomes:
Locations:
city: Buenos Aires
country: Argentina
facility: Hospital Posadas
Study officials:
affiliation: University of Buenos Aires
name: CARLOS EGHI, physician
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ayus JC, Negri AL, Moritz ML, Lee KM, Caputo D, Borda ME, Go AS, Eghi C. Hyponatremia, Inflammation at Admission, and Mortality in Hospitalized COVID-19 Patients: A Prospective Cohort Study. Front Med (Lausanne). 2021 Dec 2;8:748364. doi: 10.3389/fmed.2021.748364. eCollection 2021.
Clinical trial NCT00763568: 4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C
Official title: Study of a 4-Week Lead-In With Nitazoxanide Followed By 36 Weeks of Nitazoxanide Plus Peginterferon Alfa-2a in the Treatment of Chronic Hepatitis C
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Hepatitis C
Keywords: Chronic hepatitis C
Viral hepatitis
Lead sponsor: Romark Laboratories L.C.
Sponsor class: INDUSTRY
First posted: 2008-10-01
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if taking nitazoxanide alone for 4 weeks followed by 36 weeks of nitazoxanide plus peginterferon is superior to peginterferon plus ribavirin (standard of care) for 48 weeks.


Eligibility criteria: Inclusion Criteria:

* Chronic hepatitis C

Exclusion Criteria:

* Previously failed to respond to at least 12 weeks of peginterferon plus ribavirin combination therapy.
* Unable to take oral medication.
* Females who are either pregnant, breast-feeding or not using birth control.
* Males whose female partners are pregnant or plan to become pregnant.
* Other causes of liver disease (for example, autoimmune hepatitis, decompensated liver disease).
* Patients with HIV, HAV, HBV or HDV.
* Patients with a history of alcoholism or with an alcohol consumption of more than 40 grams per day.
* Patients with hemoglobinopathies (for example, thalassemia major, sickle-cell anemia).
* History of hypersensitivity or intolerance to nitazoxanide or peginterferon.

Primary outcomes:
measure: Sustained virologic response
timeFrame: 24 weeks after the end of treatment
Secondary outcomes:
measure: End of treatment virologic response
timeFrame: At the end of treatment
measure: Early virologic response
timeFrame: After 12 weeks of combination therapy
measure: Rapid virologic response
timeFrame: After 4 weeks of combination therapy
measure: ALT normalization
timeFrame: 24 weeks after the end of treatment
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Digestive Disease Center
Study officials:
affiliation: Tanta University School of Medicine
name: Asem Elfert, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00456768: Efficacy of Treatment for Panic Disorder
Official title: Efficacy of Treatment for Panic Disorder
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Panic Disorder
Keywords: Panic Disorder
Anxiety
Treatment efficacy
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2007-04-05
Enrollment: 250
Sex: ALL
Minimum age (years): 19
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Sampling method: PROBABILITY_SAMPLE
Study population: Patients referred to the Anxiety Disorders Clinic, Vancouver, who receive a primary diagnosis of Panic Disorder, and are accepted for treatment at the clinic.

Brief summary: The purpose of these questionnaires is to give us an overview of how panic has affected your life and perhaps also to give us some clues about things that may have set you up to experience panic.

Detailed description: For us to evaluate the efficacy of our treatment programs, we are interested in your responses before and after treatment. We use two methods to evaluate the efficacy of our treatments: questionnaires and interviews with a member of the Anxiety Disorders Clinic. As part of standard clinic procedure, each person in the program completes an in-person interview with a staff member who will determine your suitability for treatment. If you have received this questionnaire packet, it is likely that your concerns will be appropriately addressed in the Anxiety Disorders Clinic. The purpose of the questionnaire packet is to assess the severity of your panic disorder; its impact on your functioning, and factors that may contribute to the onset or maintenance of your panic (e.g., depression, anxiety sensitivity). We will ask you to complete this questionnaire again when you have completed your treatment along with a brief telephone interview with a staff member of the Anxiety Disorders Clinic.

Eligibility criteria: Inclusion Criteria:

* Patients referred to the Anxiety Disorders Clinic who receive a primary diagnosis of Panic Disorder, and are accepted for treatment at the clinic.

Exclusion Criteria:

* Individuals who either have not sought treatment for anxiety at the Anxiety Disorders Clinic or patients who did not receive a primary diagnosis of Panic Disorder.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: Anxiety Disorders Clinic, University of British Columbia
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Maureen Whittal, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06421168: Lung Function in Bariatric Surgery Candidates
Official title: The Impact of Body Mass Index on Lung Function in Bariatric Surgery Candidates
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Function Decreased
Obesity
Lead sponsor: China-Japan Friendship Hospital
Sponsor class: OTHER
First posted: 2024-05-20
Enrollment: 1834
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: CASE_CROSSOVER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Bariatric surgery candidates who completed lung function tests preoperatively were enrolled.

Brief summary: This study aims to retrospectively investigate the impact of body mass index on lung function metrics, e.g. FEV1%, FVC%, FEV1/FVC%.


Eligibility criteria: Inclusion Criteria:

* Subjects with obesity (BMI ≥ 27.5 kg/m2 according to Chinese guidelines, guidelines from the American Society for Metabolic and Bariatric Surgery and International Federation for the Surgery of Obesity and Metabolic Disorders);
* Age \> 16 years;
* Complete preoperative pulmonary function tests

Exclusion Criteria:

* Patients with a history of lung surgery and/or respiratory diseases (e.g. asthma, pulmonary emphysema, and interstitial pulmonary fibrosis).

Primary outcomes:
measure: FEV1, FVC, FEV1/FVC% in class 1, 2, and 3 obesity
timeFrame: At the time of pulmonary function testing
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Yuntao Nie
Study officials:
affiliation: China-Japan Friendship Hospital
name: Yuntao Nie, M.D.
role: STUDY_CHAIR
References: